Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/41905
Title: Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Authors: 
Mesh: 
Issue Date: 7-Oct-2017
Citation: Lancet.2017 Oct;(390)10103:1664-1675
Abstract: Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease. We investigated whether these effects would be apparent in a clinical trial.
PMID: 28781108
URI: https://hdl.handle.net/20.500.12530/41905
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC5831666.pdf695.43 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.